234 related articles for article (PubMed ID: 30254313)
1. Prediagnostic detection of mesothelioma by circulating calretinin and mesothelin - a case-control comparison nested into a prospective cohort of asbestos-exposed workers.
Johnen G; Burek K; Raiko I; Wichert K; Pesch B; Weber DG; Lehnert M; Casjens S; Hagemeyer O; Taeger D; Brüning T;
Sci Rep; 2018 Sep; 8(1):14321. PubMed ID: 30254313
[TBL] [Abstract][Full Text] [Related]
2. Calretinin as a blood-based biomarker for mesothelioma.
Johnen G; Gawrych K; Raiko I; Casjens S; Pesch B; Weber DG; Taeger D; Lehnert M; Kollmeier J; Bauer T; Musk AW; Robinson BWS; Brüning T; Creaney J
BMC Cancer; 2017 May; 17(1):386. PubMed ID: 28558669
[TBL] [Abstract][Full Text] [Related]
3. Mesothelin, Calretinin, and Megakaryocyte Potentiating Factor as Biomarkers of Malignant Pleural Mesothelioma.
Jiménez-Ramírez C; Casjens S; Juárez-Pérez CA; Raiko I; Del Razo LM; Taeger D; Calderón-Aranda ES; Rihs HP; Acosta-Saavedra LC; Weber DG; Cabello-López A; Pesch B; Ochoa-Vázquez MD; Burek K; Torre-Bouscoulet L; Pérez-Padilla JR; García-Bazan EM; Brüning T; Johnen G; Aguilar-Madrid G
Lung; 2019 Oct; 197(5):641-649. PubMed ID: 31267149
[TBL] [Abstract][Full Text] [Related]
4. Assessment of potential predictors of calretinin and mesothelin to improve the diagnostic performance to detect malignant mesothelioma: results from a population-based cohort study.
Casjens S; Weber DG; Johnen G; Raiko I; Taeger D; Meinig C; Moebus S; Jöckel KH; Brüning T; Pesch B
BMJ Open; 2017 Oct; 7(10):e017104. PubMed ID: 29025836
[TBL] [Abstract][Full Text] [Related]
5. Changes of mesothelin and osteopontin levels over time in formerly asbestos-exposed power industry workers.
Felten MK; Khatab K; Knoll L; Schettgen T; Müller-Berndorff H; Kraus T
Int Arch Occup Environ Health; 2014 Feb; 87(2):195-204. PubMed ID: 23423281
[TBL] [Abstract][Full Text] [Related]
6. Significance of serum mesothelin in an asbestos-exposed population in the Czech Republic.
Jakubec P; Pelclova D; Smolkova P; Kolek V; Nakladalova M
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Sep; 159(3):472-9. PubMed ID: 24781044
[TBL] [Abstract][Full Text] [Related]
7. Biomarkers for Predicting Malignant Pleural Mesothelioma in a Mexican Population.
Aguilar-Madrid G; Pesch B; Calderón-Aranda ES; Burek K; Jiménez-Ramírez C; Juárez-Pérez CA; Ochoa-Vázquez MD; Torre-Bouscoulet L; Acosta-Saavedra LC; Sada-Ovalle I; García-Figueroa J; Alvarado-Cabrero I; Castillo-González P; Báez-Saldaña AR; Pérez-Padilla JR; Osnaya-Juárez J; Rivera-Rosales RM; García-Bazán EM; Bautista-Aragón YL; Lazcano-Hernandez E; Munguía-Canales DA; Argote-Greene LM; Taeger D; Weber DG; Casjens S; Raiko I; Brüning T; Johnen G
Int J Med Sci; 2018; 15(9):883-891. PubMed ID: 30008600
[No Abstract] [Full Text] [Related]
8. Assessment of miR-103a-3p in leukocytes-No diagnostic benefit in combination with the blood-based biomarkers mesothelin and calretinin for malignant pleural mesothelioma diagnosis.
Jiménez-Ramírez C; Gilbert Weber D; Aguilar-Madrid G; Brik A; Juárez-Pérez CA; Casjens S; Raiko I; Brüning T; Johnen G; Cabello-López A
PLoS One; 2022; 17(10):e0275936. PubMed ID: 36240245
[TBL] [Abstract][Full Text] [Related]
9. Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin.
Ak G; Tada Y; Shimada H; Metintas S; Ito M; Hiroshima K; Tagawa M; Metintas M
BMC Cancer; 2017 Mar; 17(1):212. PubMed ID: 28335760
[TBL] [Abstract][Full Text] [Related]
10. Is soluble mesothelin-related protein an upfront predictive marker of pleural mesothelioma? A prospective study on Italian workers exposed to asbestos.
Filiberti R; Marroni P; Spigno F; Merlo DF; Mortara V; Caruso P; Cioè A; Michelazzi L; Bruzzone A; Bobbio B; Simonassi C; Del Corso L; Galli R; Racchi O; Dini G; Linares R; Mencoboni M
Oncology; 2014; 86(1):33-43. PubMed ID: 24401539
[TBL] [Abstract][Full Text] [Related]
11. Combination of mesothelin and CEA significantly improves the differentiation between malignant pleural mesothelioma, benign asbestos disease, and lung cancer.
Muley T; Dienemann H; Herth FJ; Thomas M; Meister M; Schneider J
J Thorac Oncol; 2013 Jul; 8(7):947-51. PubMed ID: 23777840
[TBL] [Abstract][Full Text] [Related]
12. Validity of mesothelin in occupational medicine practice.
Smolková P; Nakládalová M; Zapletalová J; Jakubec P; Vildová H; Kolek V; Petřek M; Nakládal Z
Int J Occup Med Environ Health; 2016; 29(3):395-404. PubMed ID: 26988879
[TBL] [Abstract][Full Text] [Related]
13. Performance of biomarkers SMRP, CA125, and CYFRA 21-1 as potential tumor markers for malignant mesothelioma and lung cancer in a cohort of workers formerly exposed to asbestos.
Gube M; Taeger D; Weber DG; Pesch B; Brand P; Johnen G; Müller-Lux A; Gross IM; Wiethege T; Weber A; Raithel HJ; Kraus T; Brüning T
Arch Toxicol; 2011 Mar; 85(3):185-92. PubMed ID: 20737138
[TBL] [Abstract][Full Text] [Related]
14. Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study.
Roe OD; Creaney J; Lundgren S; Larsson E; Sandeck H; Boffetta P; Nilsen TI; Robinson B; Kjaerheim K
Lung Cancer; 2008 Aug; 61(2):235-43. PubMed ID: 18281122
[TBL] [Abstract][Full Text] [Related]
15. Combination of MiR-103a-3p and mesothelin improves the biomarker performance of malignant mesothelioma diagnosis.
Weber DG; Casjens S; Johnen G; Bryk O; Raiko I; Pesch B; Kollmeier J; Bauer TT; Brüning T
PLoS One; 2014; 9(12):e114483. PubMed ID: 25469901
[TBL] [Abstract][Full Text] [Related]
16. HMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients.
Napolitano A; Antoine DJ; Pellegrini L; Baumann F; Pagano I; Pastorino S; Goparaju CM; Prokrym K; Canino C; Pass HI; Carbone M; Yang H
Clin Cancer Res; 2016 Jun; 22(12):3087-96. PubMed ID: 26733616
[TBL] [Abstract][Full Text] [Related]
17. Combined circulating epigenetic markers to improve mesothelin performance in the diagnosis of malignant mesothelioma.
Santarelli L; Staffolani S; Strafella E; Nocchi L; Manzella N; Grossi P; Bracci M; Pignotti E; Alleva R; Borghi B; Pompili C; Sabbatini A; Rubini C; Zuccatosta L; Bichisecchi E; Valentino M; Horwood K; Comar M; Bovenzi M; Dong LF; Neuzil J; Amati M; Tomasetti M
Lung Cancer; 2015 Dec; 90(3):457-64. PubMed ID: 26431916
[TBL] [Abstract][Full Text] [Related]
18. Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma.
Creaney J; Olsen NJ; Brims F; Dick IM; Musk AW; de Klerk NH; Skates SJ; Robinson BW
Cancer Epidemiol Biomarkers Prev; 2010 Sep; 19(9):2238-46. PubMed ID: 20651076
[TBL] [Abstract][Full Text] [Related]
19. Serum biomarkers in patients with mesothelioma and pleural plaques and healthy subjects exposed to naturally occurring asbestos.
Bayram M; Dongel I; Akbaş A; Benli I; Akkoyunlu ME; Bakan ND
Lung; 2014 Feb; 192(1):197-203. PubMed ID: 24170217
[TBL] [Abstract][Full Text] [Related]
20. Serial measurements of mesothelioma serum biomarkers in asbestos-exposed individuals: a prospective longitudinal cohort study.
Hollevoet K; Van Cleemput J; Thimpont J; De Vuyst P; Bosquée L; Nackaerts K; Germonpré P; Vansteelandt S; Kishi Y; Delanghe JR; van Meerbeeck JP
J Thorac Oncol; 2011 May; 6(5):889-95. PubMed ID: 21358346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
